Home › Melanoma › Arizona › Gilbert
Melanoma clinical trials in Gilbert, AZ
4 studies for Melanoma are looking for participants at sites in and around Gilbert (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
RecruitingPhase 3
- Banner MD Anderson Cancer Center, Gilbert
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
RecruitingPhase 1/2
- Banner MD Anderson Cancer Center, Gilbert
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
RecruitingPhase 1/2
- Banner MD Anderson Cancer Center, Gilbert
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Recruiting
- Banner MD Anderson Cancer Center, Gilbert
About Melanoma
Melanoma is the most serious type of skin cancer. Most have a black or black-blue area. Learn the 'ABCDE' of what to watch for and treatment options.
More about Melanoma on MedlinePlus
Melanoma trials in other cities
- Houston, TX59 studies
- New York City, NY38 studies
- Los Angeles, CA34 studies
- Nashville, TN33 studies
- Pittsburgh, PA31 studies
- Boston, MA26 studies
- Philadelphia, PA23 studies
- San Francisco, CA22 studies
- Durham, NC21 studies
- Atlanta, GA21 studies
- St. Louis, MO21 studies
- Salt Lake City, UT21 studies
Other studies in Gilbert
- Non-Small Cell Lung Cancer12 studies
- Colorectal Cancer9 studies
- Breast Cancer9 studies
- Lung Cancer8 studies
- Cancer (all types)8 studies
- Head and Neck Squamous Cell Carcinoma6 studies
- Metastatic Cancer6 studies
- Multiple Myeloma6 studies
- Heart Failure6 studies
- Cardiovascular Disease6 studies
- Bladder Cancer6 studies
- Non-Hodgkin Lymphoma5 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.